Pfizer ends clinical Trials of DMD drug domagrozumab after disappointing results

Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy (DMD). This decision comes after the trials failed to meet primary efficacy endpoints.

The trials, identified as B5161002 and B5161004, were designed to evaluate the safety and efficacy of domagrozumab, a humanized monoclonal antibody. Administered monthly via intravenous doses to boys aged between 6 and 15, irrespective of their underlying genetic mutation, the phase 2 study B5161002 did not demonstrate the hoped-for efficacy. After a year of treatment, the drug did not show significant improvement in the time taken by patients to climb four stairs, a key measure of motor function in DMD sufferers.

While the results were disappointing, Pfizer emphasized that the decision to end the trials was not due to safety concerns. The company plans to continue analyzing the data collected to glean further insights into the disease and explore potential applications of domagrozumab in other muscular diseases.

Seng Cheng, Senior Vice President and Chief Scientific Officer of Pfizer Rare Disease Research Unit, expressed gratitude towards the participants and their families: “We are disappointed by these results and while we are not progressing with the studies, the data will contribute to a greater understanding of this disease.”

The news is a significant blow to hopes for a new treatment option for DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. The DMD community, eagerly awaiting advancements, must now look to other ongoing research efforts for potential treatments.

The discontinuation of the domagrozumab trials underscores the challenges in developing treatments for complex diseases like DMD. While this outcome is unfortunate, it also highlights the importance of rigorous clinical testing to ensure that only effective and safe therapies reach patients.

Pfizer’s commitment to understanding and potentially treating muscular diseases remains undeterred despite these setbacks. The pharmaceutical community and patients alike await further developments with hope and cautious optimism.